Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (human)

ABSTRACT: Tumor samples were obtained from patients with metastatic melanoma before treatment with checkpoint inhibitors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE122220 | GEO | 2020/11/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (mouse)

Project description:Checkpoint inhibitors have improved outcomes for patients with metastatic melanoma, but primary or acquired resistance often occurs. We used the mouse melanoma cell line B16, originally derived from C57BL6 mice, to model changes in tumor cell gene expression that occur with acquired resistance to checkpoint inhibitors. B16 cells used were engineered to express the fluorescent marker tdTomato, to assist monitoring and cell sorting. Previously-untreated B16 cells (F0) were inoculated into C57BL6 mice, followed by treatment with triple-checkpoint inhibitor therapy (3I) with combined antibodies to CTLA4, PD-1, and PD-L1. Tumors that emerged despite immune selection pressure were harvested, grown again in vitro as a cell line, and then re-inoculated into a new generation of mice. This was repeated for 4 generations (F4) until inoculations were 100% successful at generating immune-resistant tumors.

2020-11-01 | GSE122221 | GEO

In-depth plasma proteomics in patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors or MAPK-inhibitors

Project description:Recent development of new therapies with immune checkpoint inhibitors (ICIs) and MAPK-inhibitors (MAPKis) have significantly improved the outcome in metastatic cutaneous melanoma (CM). However, therapy response is limited to subgroups of patients and clinically useful predictive biomarkers for treatment outcome are lacking. To discover treatment-related systemic changes in plasma and potential biomarkers associated with treatment outcomes, we analysed 45 plasma samples from 24 patients with metastatic (stage IV) CM, using HiRIEF LC-MS/MS, collected before (pre-trm) and during treatment (trm). Of these, 27 samples were taken from 15 metastatic CM patients treated with ICIs (13 pre-trm and 14 trm samples; 12 matched) and 9 patients treated with MAPKis (9 matched). Matched samples were trm and pre-trm samples taken from the same individual before treatment and after the first cycle of treatment (before the second cycle). We have analysed the change in the plasma protein levels during treatment by comparing the plasma levels in the trm samples to the pre-trm samples, to detect treatment-induced alterations in the plasma proteome. We have analysed the patients treated with ICIs separately from the patients treated with MAPKis, to detect treatment-specific changes for both.

2020-07-13 | PXD017201 | Pride

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors

Project description:Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors

| PRJNA504012 | ENA

DNA methylation signatures correlate with response to immune checkpoint inhibitors in metastatic melanoma

Project description:DNA methylation profiles were recently proposed to have predictive value in various solid tumors. Therefore, we analyzed DNA methylation profiles of patients with stage IV metastatic melanoma, receiving first-line immune checkpoint inhibitors (ICIs) and correlated those with radiological response (iRECIST). Overall, 81 tissue samples from 71 patients with metastatic melanoma (27 (38.0%) female, 44 (62.0%) male) were investigated; median progression free survival was 8.5 months (0 – 104.1 months) and median overall survival was 30.6 months (0 – 104.1 months), respectively. 29 (40.8%) patients achieved an objective response. DNA methylation analyses revealed signatures correlating with radiological response to ICIs. Based on the 500 mostly differentially methylated genes, three clusters were identified with the majority of responders being in cluster 1 (12/12) and cluster 2 (12/24), and non-responders in cluster 3 (39/45). Our findings indicate that tumor DNA methylation profiling may be used as a predictor for ICI-response in patients with metastatic melanoma.

2024-04-03 | GSE235122 | GEO

Tsur2019 - Response of patients with melanoma to immune checkpoint blockade

Project description:This is a simple mathematical population model for pembrolizumab-treated advanced melanoma patients, used to predict the response of melanoma patients to immune checkpoint inhibitors.

2021-10-05 | BIOMD0000000838 | BioModels

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (mouse)

Project description:Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (mouse)

| PRJNA504014 | ENA

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (human)

Project description:Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (human)

| PRJNA504015 | ENA

scRNA-seq of human PBMCs and tumor-infiltrated lymphocytes from melanoma patients analysed prior to checkpoint inhibitor treatment

Project description:We performed single-cell RNA-sequencing of tumor immune infiltrates and matched peripheral blood mononuclear cells of checkpoint inhibitor (CPI)-naive stage III-IV metastatic melanoma patients. After sample collection, the same patients received CPI-treatment and their response was assessed.

2024-04-08 | E-MTAB-13770 | biostudies-arrayexpress

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [scRNA-Seq]

Project description:Severe immune-related adverse events (irAEs) occur in up to 60% of melanoma patients treated with immune checkpoint inhibitors (ICIs). However, it remains unknown whether a common baseline immunological state precedes irAE development. Leveraging CyTOF, single-cell RNA sequencing, bulk RNA sequencing, and T cell receptor sequencing to analyze pretreatment blood from metastatic melanoma patients treated with ICIs, we investigated cellular factors associated with severe irAE development regardless of organ system involvement. Our results demonstrate circulating T cell characteristics associated with ICI-induced toxicity, with implications for improved diagnostics and clinical management.

2022-01-13 | GSE189125 | GEO

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [bulk RNA-seq]

2022-01-13 | GSE186143 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data